Single-Gene Congenic Strain Reveals the Effect of Zbtb16 on Dexamethasone-Induced Insulin Resistance
BackgroundGlucocorticoids (GCs) are potent therapeutic agents frequently used for treatment of number of conditions, including hematologic, inflammatory, and allergic diseases. Both their therapeutic and adverse effects display significant interindividual variation, partially attributable to genetic...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-04-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fendo.2018.00185/full |
id |
doaj-9c7cdc0d50c44b5db42f54f46828053e |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Michaela Krupková František Liška Ludmila Kazdová Lucie Šedová Lucie Šedová Adéla Kábelová Drahomíra Křenová Vladimír Křen Ondřej Šeda |
spellingShingle |
Michaela Krupková František Liška Ludmila Kazdová Lucie Šedová Lucie Šedová Adéla Kábelová Drahomíra Křenová Vladimír Křen Ondřej Šeda Single-Gene Congenic Strain Reveals the Effect of Zbtb16 on Dexamethasone-Induced Insulin Resistance Frontiers in Endocrinology ZBTB16 dexamethasone rat models congenic strain pharmacogenetics and pharmacogenomics insulin resistance |
author_facet |
Michaela Krupková František Liška Ludmila Kazdová Lucie Šedová Lucie Šedová Adéla Kábelová Drahomíra Křenová Vladimír Křen Ondřej Šeda |
author_sort |
Michaela Krupková |
title |
Single-Gene Congenic Strain Reveals the Effect of Zbtb16 on Dexamethasone-Induced Insulin Resistance |
title_short |
Single-Gene Congenic Strain Reveals the Effect of Zbtb16 on Dexamethasone-Induced Insulin Resistance |
title_full |
Single-Gene Congenic Strain Reveals the Effect of Zbtb16 on Dexamethasone-Induced Insulin Resistance |
title_fullStr |
Single-Gene Congenic Strain Reveals the Effect of Zbtb16 on Dexamethasone-Induced Insulin Resistance |
title_full_unstemmed |
Single-Gene Congenic Strain Reveals the Effect of Zbtb16 on Dexamethasone-Induced Insulin Resistance |
title_sort |
single-gene congenic strain reveals the effect of zbtb16 on dexamethasone-induced insulin resistance |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Endocrinology |
issn |
1664-2392 |
publishDate |
2018-04-01 |
description |
BackgroundGlucocorticoids (GCs) are potent therapeutic agents frequently used for treatment of number of conditions, including hematologic, inflammatory, and allergic diseases. Both their therapeutic and adverse effects display significant interindividual variation, partially attributable to genetic factors. We have previously isolated a seven-gene region of rat chromosome 8 sensitizing to dexamethasone (DEX)-induced dyslipidemia and insulin resistance (IR) of skeletal muscle. Using two newly derived congenic strains, we aimed to investigate the effect of one of the prime candidates for this pharmacogenetic interaction, the Zbtb16 gene.MethodsAdult male rats of SHR-Lx.PD5PD-Zbtb16 (n = 9) and SHR-Lx.PD5SHR-Zbtb16 (n = 8) were fed standard diet (STD) and subsequently treated with DEX in drinking water (2.6 µg/ml) for 3 days. The morphometric and metabolic profiles of both strains including oral glucose tolerance test, triacylglycerols (TGs), free fatty acids, insulin, and C-reactive protein levels were assessed before and after the DEX treatment. Insulin sensitivity of skeletal muscle and visceral adipose tissue was determined by incorporation of radioactively labeled glucose.ResultsThe differential segment of SHR-Lx.PD5SHR-Zbtb16 rat strain spans 563 kb and contains six genes: Htr3a, Htr3b, Usp28, Zw10, Tmprss5, and part of Drd2. The SHR-Lx.PD5PD-Zbtb16 minimal congenic strain contains only Zbtb16 gene on SHR genomic background and its differential segment spans 254 kb. Total body weight was significantly increased in SHR-Lx.PD5PD-Zbtb16 strain compared with SHR-Lx.PD5SHR-Zbtb16, however, no differences in the weights of adipose tissue depots were observed. While STD-fed rats of both strains did not show major differences in their metabolic profiles, after DEX treatment the SHR-Lx.PD5PD-Zbtb16 congenic strain showed increased levels of TGs, glucose, and blunted inhibition of lipolysis by insulin. Both basal and insulin-stimulated incorporation of radioactively labeled glucose into skeletal muscle glycogen were significantly reduced in SHR-Lx.PD5PD-Zbtb16 strain, but the insulin sensitivity of adipose tissue was comparable between the two strains.ConclusionThe metabolic disturbances including impaired glucose tolerance, dyslipidemia, and IR of skeletal muscle observed after DEX treatment in the congenic SHR-Lx.PD5PD-Zbtb16 reveal the Zbtb16 locus as a possible sensitizing factor for side effects of GC therapy. |
topic |
ZBTB16 dexamethasone rat models congenic strain pharmacogenetics and pharmacogenomics insulin resistance |
url |
http://journal.frontiersin.org/article/10.3389/fendo.2018.00185/full |
work_keys_str_mv |
AT michaelakrupkova singlegenecongenicstrainrevealstheeffectofzbtb16ondexamethasoneinducedinsulinresistance AT frantisekliska singlegenecongenicstrainrevealstheeffectofzbtb16ondexamethasoneinducedinsulinresistance AT ludmilakazdova singlegenecongenicstrainrevealstheeffectofzbtb16ondexamethasoneinducedinsulinresistance AT luciesedova singlegenecongenicstrainrevealstheeffectofzbtb16ondexamethasoneinducedinsulinresistance AT luciesedova singlegenecongenicstrainrevealstheeffectofzbtb16ondexamethasoneinducedinsulinresistance AT adelakabelova singlegenecongenicstrainrevealstheeffectofzbtb16ondexamethasoneinducedinsulinresistance AT drahomirakrenova singlegenecongenicstrainrevealstheeffectofzbtb16ondexamethasoneinducedinsulinresistance AT vladimirkren singlegenecongenicstrainrevealstheeffectofzbtb16ondexamethasoneinducedinsulinresistance AT ondrejseda singlegenecongenicstrainrevealstheeffectofzbtb16ondexamethasoneinducedinsulinresistance |
_version_ |
1725323470467760128 |
spelling |
doaj-9c7cdc0d50c44b5db42f54f46828053e2020-11-25T00:31:09ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922018-04-01910.3389/fendo.2018.00185312957Single-Gene Congenic Strain Reveals the Effect of Zbtb16 on Dexamethasone-Induced Insulin ResistanceMichaela Krupková0František Liška1Ludmila Kazdová2Lucie Šedová3Lucie Šedová4Adéla Kábelová5Drahomíra Křenová6Vladimír Křen7Ondřej Šeda8The First Faculty of Medicine, Institute of Biology and Medical Genetics, Charles University, The General Teaching Hospital, Prague, CzechiaThe First Faculty of Medicine, Institute of Biology and Medical Genetics, Charles University, The General Teaching Hospital, Prague, CzechiaCentre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, CzechiaThe First Faculty of Medicine, Institute of Biology and Medical Genetics, Charles University, The General Teaching Hospital, Prague, CzechiaLaboratory of Transgenic Models of Diseases, Division BIOCEV, Institute of Molecular Genetics of the Czech Academy of Sciences, v.v.i., Vestec, Prague, CzechiaThe First Faculty of Medicine, Institute of Biology and Medical Genetics, Charles University, The General Teaching Hospital, Prague, CzechiaThe First Faculty of Medicine, Institute of Biology and Medical Genetics, Charles University, The General Teaching Hospital, Prague, CzechiaThe First Faculty of Medicine, Institute of Biology and Medical Genetics, Charles University, The General Teaching Hospital, Prague, CzechiaThe First Faculty of Medicine, Institute of Biology and Medical Genetics, Charles University, The General Teaching Hospital, Prague, CzechiaBackgroundGlucocorticoids (GCs) are potent therapeutic agents frequently used for treatment of number of conditions, including hematologic, inflammatory, and allergic diseases. Both their therapeutic and adverse effects display significant interindividual variation, partially attributable to genetic factors. We have previously isolated a seven-gene region of rat chromosome 8 sensitizing to dexamethasone (DEX)-induced dyslipidemia and insulin resistance (IR) of skeletal muscle. Using two newly derived congenic strains, we aimed to investigate the effect of one of the prime candidates for this pharmacogenetic interaction, the Zbtb16 gene.MethodsAdult male rats of SHR-Lx.PD5PD-Zbtb16 (n = 9) and SHR-Lx.PD5SHR-Zbtb16 (n = 8) were fed standard diet (STD) and subsequently treated with DEX in drinking water (2.6 µg/ml) for 3 days. The morphometric and metabolic profiles of both strains including oral glucose tolerance test, triacylglycerols (TGs), free fatty acids, insulin, and C-reactive protein levels were assessed before and after the DEX treatment. Insulin sensitivity of skeletal muscle and visceral adipose tissue was determined by incorporation of radioactively labeled glucose.ResultsThe differential segment of SHR-Lx.PD5SHR-Zbtb16 rat strain spans 563 kb and contains six genes: Htr3a, Htr3b, Usp28, Zw10, Tmprss5, and part of Drd2. The SHR-Lx.PD5PD-Zbtb16 minimal congenic strain contains only Zbtb16 gene on SHR genomic background and its differential segment spans 254 kb. Total body weight was significantly increased in SHR-Lx.PD5PD-Zbtb16 strain compared with SHR-Lx.PD5SHR-Zbtb16, however, no differences in the weights of adipose tissue depots were observed. While STD-fed rats of both strains did not show major differences in their metabolic profiles, after DEX treatment the SHR-Lx.PD5PD-Zbtb16 congenic strain showed increased levels of TGs, glucose, and blunted inhibition of lipolysis by insulin. Both basal and insulin-stimulated incorporation of radioactively labeled glucose into skeletal muscle glycogen were significantly reduced in SHR-Lx.PD5PD-Zbtb16 strain, but the insulin sensitivity of adipose tissue was comparable between the two strains.ConclusionThe metabolic disturbances including impaired glucose tolerance, dyslipidemia, and IR of skeletal muscle observed after DEX treatment in the congenic SHR-Lx.PD5PD-Zbtb16 reveal the Zbtb16 locus as a possible sensitizing factor for side effects of GC therapy.http://journal.frontiersin.org/article/10.3389/fendo.2018.00185/fullZBTB16dexamethasonerat modelscongenic strainpharmacogenetics and pharmacogenomicsinsulin resistance |